Edition:
United States

CorMedix Inc (CRMD.A)

CRMD.A on American Stock Exchange

0.42USD
18 Aug 2017
Change (% chg)

$-0.00 (-1.18%)
Prev Close
$0.43
Open
$0.44
Day's High
$0.44
Day's Low
$0.41
Volume
89,859
Avg. Vol
45,461
52-wk High
$3.25
52-wk Low
$0.32

Latest Key Developments (Source: Significant Developments)

Cormedix Q2 net loss of $0.10 per share​
Wednesday, 9 Aug 2017 05:05pm EDT 

Aug 9 (Reuters) - Cormedix Inc ::Cormedix Inc - ‍for Q2 2017, Cormedix recorded a net loss of $0.10 per share​.Cormedix Inc - ‍at June 30, 2017, co had $18.8 million in cash, short-term investments compared to $13.8 million at March 31, 2017, a net increase of $5.0 million​.  Full Article

Cormedix Inc provides update on Neutrolin ongoing Phase 3 clinical trial
Wednesday, 2 Aug 2017 10:00am EDT 

Aug 2 (Reuters) - Cormedix Inc ::Cormedix inc provides update on Neutrolin ongoing Phase 3 clinical trial following FDA correspondence.Says Co believes changes endorsed by FDA will facilitate co's ability to complete on-going Phase 3 study as previously announced by year-end 2018.Says sought FDA'S guidance to address, in part, apparent overall lower rate of catheter-related blood stream infection events as announced in April.Says based on review of status of ongoing Lock-It-100 clinical study and a revised plan put forth by Cormedix, FDA agreed to key changes to study.Says it is reassessing structure of its second planned Phase 3 study to seek possible efficiencies and improvements in its design and execution.Says changes will allow identification of more infections, enabling single interim analysis anticipated to occur in Q4 2017 based on 28 CRBSI events.Says it anticipates this process will be completed within next several months.  Full Article

CVI Investments Inc reports 6.7 pct passive stake in Cormedix Inc
Monday, 8 May 2017 02:05pm EDT 

May 8 (Reuters) - Cormedix Inc ::CVI Investments Inc reports 6.7 percent passive stake in Cormedix Inc as on April 28, 2017 - SEC filing.  Full Article

Cormedix announced an update in ongoing U.S. Phase 3 "lock-it 100" clinical trial of its lead product candidate neutrolin - SEC Filing
Thursday, 20 Apr 2017 09:33am EDT 

April 20 (Reuters) - Cormedix Inc :Cormedix Inc- Announced an update in ongoing U.S. Phase 3 "lock-it 100" clinical trial of its lead product candidate neutrolin - SEC filing.Cormedix - Has to date enrolled 368 patients in lock-it 100 clinical trial, recently completed safety review by independent data and safety monitoring board.Cormedix - DSMB unanimously concluded it is safe to continue trial as designed based on evaluation of data from first 279 patients randomized on trial.Cormedix Inc- Topline results expected to be available around year-end 2018 in phase 3 "lock-it 100" for neutrolin.Cormedix Inc- Currently in discussions with FDA regarding possible prospective changes to protocol for clinical trial.Cormedix Inc - FDA has accepted co's proposal to include one or more interim efficacy analyses of trial data while lock-it 100 is ongoing.  Full Article

Cormedix Q2 loss per share $0.13
Friday, 5 Aug 2016 08:05am EDT 

Cormedix Inc : Qtrly loss per share $0.13 .Qtrly revenue $16,511 versus $119,973.  Full Article

CorMedix says quarterly loss of $0.12 per share
Wednesday, 11 May 2016 08:56am EDT 

Cormedix Inc - : For quarter ended march 31, 2016, CorMedix recorded a loss of $0.12 per share .Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Cormedix Q2 net loss of $0.10 per share​

* Cormedix Inc - ‍for Q2 2017, Cormedix recorded a net loss of $0.10 per share​